Una bomba de insulina es un pequeño dispositivo que puede ayudarlo a tratar la diabetes. Administra dosis continuas y personalizadas de insulina de acción rápida las 24 horas del día para satisfacer las necesidades del cuerpo. La bomba administra insulina en el cuerpo de dos maneras:
La bomba administra insulina en el cuerpo a través de un tubo delgado y flexible denominado equipo de infusión.
Varias piezas funcionan en conjunto para administrar dosis continuas de insulina.
Desplácese sobre los componentes que aparecen a continuación para obtener más información.
Las personas pueden experimentar muchos cambios positivos en sus vidas cuando pasan a la terapia con bomba.
Con la bomba de insulina, solo deberá insertar un equipo de infusión cada pocos días. En el caso de las múltiples inyecciones diarias, las personas suelen inyectarse varias veces al día.
La calculadora de bolos elimina los cálculos complejos y realiza un seguimiento de la insulina activa. El seguimiento de la insulina activa ayuda a evitar la acumulación de insulina y los niveles bajos.
Puede ayudarlo a lograr mejor control de la glucosa sin tantos altibajos.†
Consulte a un profesional de atención médica sobre la terapia con bomba de insulina si usted reúne los siguientes requisitos:
La bomba de insulina se puede llevar de muchas formas diferentes. Se puede usar cómodamente durante el trabajo, la actividad física, las ocasiones formales y la vida diaria. Desplácese sobre las imágenes que aparecen a continuación para descubrir cómo otras personas usan su bomba.
Cuando se habla del tratamiento de la diabetes, el costo no debería ser un obstáculo para acceder a tecnología avanzada para la diabetes. Nuestro equipo trabajará a su lado para que pueda experimentar los beneficios de la terapia con bomba de insulina.
SEGURO PRIVADO‡
La mayor parte de las compañías de seguro privadas cubren las bombas de insulina en la sección de equipos médicos duraderos de su póliza. Según su cobertura de seguro, es posible que deba pagar un deducible o un porcentaje del costo (coseguro). Si ha alcanzado el deducible y el desembolso máximo, su seguro podría cubrir la bomba de insulina en un 100%.
SEGURO DEL GOBIERNO‡
Los seguros gubernamentales, tales como Medicare y Medicaid, pueden cubrir las bombas de insulina en función del estado y otros requisitos. El costo de desembolso de un paciente que posee un seguro del gobierno varía según la póliza.
PROCESAMIENTO DEL SEGURO
Cuando inicia el proceso para obtener una bomba de insulina, no debe preocuparse por la documentación. Medtronic lo ayudará en cada paso del proceso verificando su seguro, proporcionando un costo estimado de desembolso, recopilando sus documentos y los de su médico, y enviando los documentos requeridos a su compañía de seguro.
OPCIONES DE PAGO
Si no tiene seguro o necesita ayuda con el costo de desembolso, Medtronic ofrece opciones flexibles de pago y un programa de asistencia financiera para los clientes que reúnen las condiciones.
El único sistema con tecnología de detección de comidas**que ajusta y corrige automáticamente† los niveles de glucosa cada 5 minutos§.
La bomba de insulina MiniMed™ 630G administra dosis precisas de insulina en el cuerpo. Cuando se combina con nuestro MCG, actúa por usted con la función Suspensión en el límite bajo de SmartGuard™, que le brinda protección y lo ayuda a mantener estables los niveles de glucosa.∆ ,3
* En el momento de la fabricación y cuando el reservorio y el tubo están bien insertados, la bomba es impermeable. Está protegida de los efectos de una inmersión en agua a una profundidad hasta de 3,6 metros (12 pies) durante un máximo de 24 horas. Está clasificada como IPX8. Para obtener más detalles, consulte la guía del usuario. El sensor y el transmisor son resistentes al agua a una profundidad de 2,4 metros (8 pies) durante un máximo de 30 minutos. Es posible que las lecturas del MCG no se transmitan desde el MCG a la bomba mientras se encuentra en el agua.
∆ ADVERTENCIA: No use la función Suspensión en el límite bajo para prevenir o tratar un nivel bajo de glucosa. Confirme siempre la lectura de glucosa del sensor con el medidor de glucosa en la sangre y siga las instrucciones del profesional de atención médica para tratar los niveles bajos de glucosa. El uso de la función Suspensión en el límite bajo de forma aislada para prevenir o tratar niveles bajos de glucosa puede causar una hipoglucemia prolongada.
‡ Los lineamientos de cobertura para las bombas de insulina varían y están sujetos a las pólizas médicas publicadas por las compañías de seguro en vigencia al momento en que se solicitan los servicios.
**Tomar un bolo de 15 a 20 minutos antes de una comida proporciona una mejora significativa en el control posterior a la comida. Recomendamos tomar un bolo de comida.
† Se refiere a la corrección automática, que brinda asistencia de bolo. Puede administrar todas las dosis de corrección automáticamente sin la interacción del usuario, la función se puede activar y desactivar.
§ Se refiere a la función SmartGuard™. Se requiere alguna interacción del usuario. Los resultados individuales pueden variar.
Φ MCG opcional
1. Heinemann L, Weyer C, Rauhaus M, Heinrichs S, Heise T. Variability of the metabolic effect of soluble insulin and the rapid-acting insulin anolog insulin aspart.Diabetes Care.1998;21:1910-1914.
2. Heise T, Nosek L, Ronn BB, et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes. 2004;53:1614-1620.
3. Bergenstal RM,Tamborlane WV, Ahmann A, et al. Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N Engl J Med. 2010;363:311–320.
Las personas fotografiadas y citadas en esta sección recibieron una compensación por el tiempo dedicado y por permitirnos fotografiarlas a ellas y sus familias. Los pensamientos y las opiniones de estas personas son propios.
Important Safety Information: MiniMed™ 770G System With SmartGuard™ Technology
The MiniMed™ 770G system is intended for continuous delivery of basal insulin (at user selectable rates) and administration of insulin boluses (in user selectable amounts) for the management of type 1 diabetes mellitus in persons two years of age and older requiring insulin as well as for the continuous monitoring and trending of glucose levels in the fluid under the skin. The MiniMed™ 770G System includes SmartGuard™ technology, which can be programmed to automatically adjust delivery of basal insulin based on continuous glucose monitoring (CGM) sensor glucose values (SG) and can suspend delivery of insulin when the SG value falls below or is predicted to fall below predefined threshold values.
The Medtronic MiniMed™ 770G System consists of the following devices: MiniMed™ 770G Insulin Pump, the Guardian™ Link (3) Transmitter, the Guardian™ Sensor (3), one-press serter, the Accu-Chek® Guide Link blood glucose meter, and the AccuChek®Guide Test Strips. The system requires a prescription.
The Guardian™ Sensor (3) has not been evaluated and is not intended to be used directly for making therapy adjustments, but rather to provide an indication of when a fingerstick may be required. All therapy adjustments should be based on measurements obtained using a blood glucose meter and not on values provided by the Guardian™ Sensor (3).
All therapy adjustments should be based on measurements obtained using the Accu-Chek® Guide Link blood glucose meter and not on values provided by the Guardian™ Sensor (3). Always check the pump display to ensure the glucose result shown agrees with the glucose results shown on the Accu-Chek® Guide Link blood glucose meter. Do not calibrate your CGM device or calculate a bolus using a blood glucose meter result taken from an alternative site. It is not recommended to calibrate your CGM device when sensor or blood glucose values are changing rapidly, e.g., following a meal or physical exercise.
WARNING: Do not use the SmartGuard™ Auto Mode for people who require less than 8 units or more than 250 units of total daily insulin per day. A total daily dose of at least 8 units, but no more than 250 units, is required to operate in SmartGuard™ Auto Mode.
WARNING: Do not use the MiniMed™ 770G system until appropriate training has been received from a healthcare professional. Training is essential to ensure the safe use of the MiniMed™ 770G system.
Pump therapy is not recommended for people whose vision or hearing does not allow recognition of pump signals and alarms. Pump therapy is not recommended for people who are unwilling or unable to maintain contact with their healthcare professional. The safety of the MiniMed™ 770G system has not been studied in pregnant women. For complete details of the system, including product and important safety information such as indications, contraindications, warnings and precautions associated with system and its components, please consult https://www.medtronicdiabetes.com/important-safetyinformation#minimed-770g and the appropriate user guide at https://www.medtronicdiabetes.com/download-library
Important Safety Information: MiniMed™ 670G System
The Medtronic MiniMed™ 670G system is intended for continuous delivery of basal insulin (at user selectable rates) and administration of insulin boluses (in user selectable amounts) for the management of type 1 diabetes mellitus in persons, seven years of age and older, requiring insulin as well as for the continuous monitoring and trending of glucose levels in the fluid under the skin. The MiniMed™ 670G system includes SmartGuard™ technology, which can be programmed to automatically adjust delivery of basal insulin based on Continuous Glucose Monitor sensor glucose values, and can suspend delivery of insulin when the sensor glucose value falls below or is predicted to fall below predefined threshold values. The system requires a prescription. The Guardian™ Sensor (3) glucose values are not intended to be used directly for making therapy adjustments, but rather to provide an indication of when a fingerstick may be required. A confirmatory finger stick test via the CONTOUR®NEXT LINK 2.4 blood glucose meter is required prior to making adjustments to diabetes therapy. All therapy adjustments should be based on measurements obtained using the CONTOUR®NEXT LINK 2.4 blood glucose meter and not on values provided by the Guardian™ Sensor (3). Always check the pump display to ensure the glucose result shown agrees with the glucose results shown on the CONTOUR®NEXT LINK 2.4 blood glucose meter. Do not calibrate your CGM device or calculate a bolus using a blood glucose meter result taken from an Alternative Site (palm) or from a control solution test. It is not recommended to calibrate your CGM device when sensor or blood glucose values are changing rapidly, e.g., following a meal or physical exercise. If a control solution test is out of range, please note that the result may be transmitted to your pump when in the “Always” send mode.
WARNING: Medtronic performed an evaluation of the MiniMed™ 670G system and determined that it may not be safe for use in children under the age of 7 because of the way that the system is designed and the daily insulin requirements. Therefore this device should not be used in anyone under the age of 7 years old. This device should also not be used in patients who require less than a total daily insulin dose of 8 units per day because the device requires a minimum of 8 units per day to operate safely.
Pump therapy is not recommended for people whose vision or hearing does not allow recognition of pump signals and alarms. Pump therapy is not recommended for people who are unwilling or unable to maintain contact with their healthcare professional. The safety of the MiniMed™ 670G system has not been studied in pregnant women. For complete details of the system, including product and important safety information such as indications, contraindications, warnings and precautions associated with system and its components, please consult http://www.medtronicdiabetes.com/important-safety-information#minimed-670g and the appropriate user guide at http://www.medtronicdiabetes.com/download-library.
Important Safety Information: MiniMed™ 630G System
Indicated for the continuous delivery of insulin, at set and variable rates, for the management of diabetes mellitus. MiniMed™ 630G system is approved for ages 14 years or older with Guardian™ Sensor 3 and MiniMed™ 630G system is approved for ages 16 years or older with Enlite™ sensor. Both systems require a prescription. Insulin infusion pumps and associated components of insulin infusion systems are limited to sale by or on the order of a physician and should only be used under the direction of a healthcare professional familiar with the risks of insulin pump therapy. Pump therapy is not recommended for people who are unwilling or unable to perform a minimum of four blood glucose tests per day. Pump therapy is not recommended for people who are unwilling or unable to maintain contact with their healthcare professional. Pump therapy is not recommended for people whose vision or hearing does not allow recognition of pump signals and alarms. Insulin pumps use rapid-acting insulin. If your insulin delivery is interrupted for any reason, you must be prepared to replace the missed insulin immediately. Replace the infusion set every 48–72 hours, or more frequently per your healthcare professional’s instructions. Insertion of a glucose sensor may cause bleeding or irritation at the insertion site. Consult a physician immediately if you experience significant pain or if you suspect that the site is infected. The information provided by CGM systems is intended to supplement, not replace, blood glucose information obtained using a blood glucose meter. A confirmatory fingerstick using a CONTOUR®NEXT LINK 2.4 meter is required prior to making adjustments to diabetes therapy. Always check the pump display when using a CONTOUR®NEXT LINK 2.4 meter, to ensure the glucose result shown agrees with the glucose results shown on the meter. Do not calibrate your CGM device or calculate a bolus using a result taken from an Alternative Site (palm) or a result from a control solution test. If a control solution test is out of range, please note that the result may be transmitted to your pump when in the “Always” send mode. It is not recommended to calibrate your CGM device when sensor or blood glucose values are changing rapidly, e.g., following a meal or physical exercise. The MiniMed™ 630G system is not intended to be used directly for preventing or treating hypoglycemia but to suspend insulin delivery when the user is unable to respond to the Suspend on low alarm and take measures to prevent or treat hypoglycemia themselves. Therapy to prevent or treat hypoglycemia should be administered according to the recommendations of the user’s healthcare provider.
WARNING: The SmartGuard™ Suspend on low feature will cause the pump to temporarily suspend insulin delivery for two hours when the sensor glucose reaches a set threshold. Under some conditions of use the pump can suspend again, resulting in very limited insulin delivery. Prolonged suspension can increase the risk of serious hyperglycemia, ketosis, and ketoacidosis. Before using the SmartGuard feature, it is important to read the SmartGuard™ feature information in the User Guide and discuss proper use of the feature with your healthcare provider.
See important safety information and the appropriate user guides for additional important details.